Binding site of activators of the cystic fibrosis transmembrane conductance regulator in the nucleotide binding domains
- 1 February 2005
- journal article
- research article
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 62 (4) , 446-460
- https://doi.org/10.1007/s00018-004-4422-3
Abstract
The use of substances that could activate the defective chloride channels of the mutant cystic fibrosis transmembrane conductance regulator (CFTR) has been suggested as possible therapy for cystic fibrosis. Using epithelia formed by cells stably transfected with wildtype or mutant (G551D, G1349D) CFTR, we estimated the apparent dissociation constant, KD, of a series of CFTR activators by measuring the increase in the apical membrane current. Modification of apparent KD of CFTR activators by mutations of the nucleotide-binding domains (NBDs) suggests that the binding site might be in these regions. The human NBD structure was predicted by homology with murine NBD1. An NBD1-NBD2 complex was constructed by overlying monomers to a bacterial ABC transporter NBD dimer in the ‘head-to- tail’ conformation. Binding sites for CFTR activators were predicted by molecular docking. Comparison of theoretical binding free energy estimated in the model to free energy estimated from the apparent dissociation constants, KD, resulted in a remarkably good correlation coefficient for one of the putative binding sites, located in the interface between NBD1 and NBD2.Keywords
This publication has 51 references indexed in Scilit:
- Dose‐dependent effect of androgen deprivation therapy for localized prostate cancer on adverse cardiac eventsBJU International, 2015
- Disease Control Outcomes from Analysis of Pooled Individual Patient Data from Five Comparative Randomised Clinical Trials of Degarelix Versus Luteinising Hormone-releasing Hormone AgonistsEuropean Urology, 2014
- The Heart: A Novel Gonadotrophin-Releasing Hormone TargetJournal of Neuroendocrinology, 2011
- Androgen Deprivation Therapy in Prostate Cancer and Metabolic Risk for AtherosclerosisJournal of Clinical Endocrinology & Metabolism, 2008
- Testosterone Reduces Macrophage Expression in the Mouse of Toll-Like Receptor 4, a Trigger for Inflammation and Innate ImmunityBiology of Reproduction, 2008
- Testosterone protects rat hearts against ischaemic insults by enhancing the effects of α1‐adrenoceptor stimulationBritish Journal of Pharmacology, 2008
- Insulin Sensitivity during Combined Androgen Blockade for Prostate CancerJournal of Clinical Endocrinology & Metabolism, 2006
- Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemiaClinical Science, 2003
- Human Peripheral Blood Mononuclear Cells Express Gonadotropin-Releasing Hormone (GnRH), GnRH Receptor, and Interleukin-2 Receptor γ-Chain Messenger Ribonucleic Acids That Are Regulated by GnRHin Vitro1Journal of Clinical Endocrinology & Metabolism, 1999
- Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia.1995